Chart Buy Signals After Co. Targeting U.S. Alzheimer's Market Reports Final Major Regulatory Milestone
Contributed Technical Analyst Opinion

Important Disclosures:

1. Grey Matters Health Inc. is a billboard sponsor of Streetwise Reports. The company pays a monthly sponsorship fee of US$3,000–US$6,000 for banner advertising and an enhanced company profile page. Streetwise Reports’ editorial content is fully independent and is not influenced by sponsorship. In addition, Grey Matters Health Inc. has a consulting relationship with Street Smart an affiliate of Streetwise Reports. Street Smart Clients pay a monthly consulting fee between US$8,000 and US$20,000
2. Grey Matters Health Inc. has paid Street Smart (an affiliate of Streetwise Reports) a fee of US$3,000 for the preparation of an independent technical research report. 
3. As of the date of this article, officers, contractors, shareholders, and/or employees of Streetwise Reports LLC (including members of their household) own securities of Grey Matters Health Inc.
4. Author Certification and Compensation: Stewart Thomson was retained and compensated as an independent contractor by Street Smart for writing this article. Mr. Thomson is a retired Canadian financial advisor who has passed the Canadian Securities Course as well as additional technical analysis courses that were mandated by his former employer and approved by Ontario regulatory bodies. Mr. Thomson is not an investment advisor. He does not know the financial situation or risk tolerance of any reader. For the past 15 years, he has been editing and writing numerous financial newsletters that have a strong focus on charts. The recommendations and opinions expressed in this content reflect the personal, independent, and objective views of the author regarding any and all of the companies discussed. No part of the compensation received by the author was, is, or will be directly or indirectly tied to the specific recommendations or views expressed. Mr. Thomson owns no securities in Grey Matters Health Inc., and he has no direct financial relationship with the company.
5. Statements and opinions expressed are the opinions of the author and not of Streetwise Reports, Street Smart, or their officers. The author is wholly responsible for the accuracy of the statements. Streetwise Reports requires contributing authors to disclose any shareholdings in, or economic relationships with, companies that they write about. Any disclosures from the author can be found below. Streetwise Reports relies upon the authors to accurately provide this information and Streetwise Reports has no means of verifying its accuracy.
6. This article does not constitute investment advice and is not a solicitation for any investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Each reader is encouraged to consult with his or her personal financial adviser and perform their own comprehensive investment research. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. Streetwise Reports does not endorse or recommend the business, products, services, or securities of any company.
7. This article does not constitute medical advice. Officers, employees and contributors to Streetwise Reports are not licensed medical professionals. Readers should always contact their healthcare professionals for medical advice.

Grey Matters Health Inc. (GREY:CSE; AGNPF:OTCQB; AGW0:FRA) is a Canadian healthcare company planning to build a national network of brain-specific PET scanning clinics, targeting a US$9.2 billion Alzheimer's diagnostics market that is projected to reach US$10.2 billion in 2026. Each NovaScan Neuroimaging Clinic™ uses an FDA-cleared CareMiBrain scanner.

There are plans to scale to 200 locations nationally. Following its April 2026 rebrand from Algernon Health and a 10:1 share consolidation, the imaging clinic business is planned to be a near-term cash generator, with a legacy drug pipeline providing longer-term optionality.

 In June of this year, Grey Matters closed a CA$1.25M private placement to fund its first U.S. clinic. In July, it took delivery of the first FDA-cleared CareMiBrain™ system for its Davie clinic, featuring brain-only imaging with 25% less radiation and a seated patient design.

On August 19, Grey Matters announced it has signed a professional services agreement with ProScan Reading Services, a nationally recognized neuroradiology firm, to interpret brain PET scans.

A day later, the company received its Radioactive Materials License from the State of Florida, which is the last major regulatory step needed for a clear path to scan the first patient by September 30. The charts show the bulls are taking control, and a revaluation of the company appears warranted.

Grey Matters announced on September 10, 2026, the closing of the first tranche (the "First Tranche") of its non-brokered private placement previously announced on August 20, 2026.

Gross Proceeds from the First Tranche total CA$600,000, consisting of CA$285,000 from the sale of 712,500 units at CA$0.40 and CA$315,000 from the sale of unsecured convertible debenture units.

Why Healthcare?

Investing in healthcare offers a unique combination of defensive stability and long-term growth potential, driven by essential, non-discretionary demand that remains resilient during economic downturns.

The sector has historically provided consistent earnings growth and lower volatility compared to broader markets, making it a critical tool for portfolio diversification and protection against inflation.

Figure 1: IYC:NYSE US Healthcare ETF Chart

Technical Analysis & Observations:

• A ten-year uptrend is evident.
• Volume is supportive, rising on rallies.
• The Stochastics momentum oscillator is on a buy signal.
• The CMF money flows indicator is in bull mode.
• OBV (on balance volume) is confirming the price action, hitting record highs.
• Moving averages are bullish.

Fundamental Share Price Catalysts

1. Davie Clinic Opening (Q3 2026): The first U.S.-dedicated brain PET clinic is imminent, with major licenses secured and the CareMiBrain system installed. The company says its scans are covered by Medicare, Medicaid, and private insurance, with a minimum reimbursement figure of US$4,500 per scan cited in its investor materials.
2. Catalyst MedTech Partnership: Catalyst MedTech is the exclusive U.S. distributor of CareMiBrain under a more than CA$4 million supply, financing, and services agreement with the company.
3. PET Scans: Separately, Grey Matters signed a non-binding LOI for an Alzheimer's clinical trial at a planned second location in Tampa. The non-binding LOI for a minimum of 200 PET scans could provide an initial revenue opportunity if converted into a definitive services agreement.
4. 200-Clinic U.S. Network: Management plans a national network of 200 NovaScan locations, each requiring approximately US$1.1 million in capital. Partnerships with GE HealthCare (tracer supply) and ProScan Reading Services (radiology interpretation) de-risk operational execution.
5. Structural Demand Tailwind: Two FDA-approved monoclonal antibody treatments for Alzheimer's require a positive beta-amyloid PET scan before therapy can begin, creating a durable, growing demand driver. Approximately 158 Alzheimer's drug candidates are currently being evaluated in clinical trials, creating a potential market for brain PET imaging services as drug programs advance.
6. Legacy Drug Pipeline: Repirinast (NP-251) for chronic kidney disease and a proprietary DMT program for stroke/TBI recovery remain active, alongside a 20% equity stake in Seyltx (Ifenprodil for chronic coughs).

Grey Matters Versus Competitors

• Large imaging networks: RadNet (RDNT:NASDAQ) offers PET/CT as one service among many, but Grey Matters' brain-dedicated, seated-patient, lower-radiation model is a differentiated experience no large network currently offers.
• Regional PET specialists: The PET Imaging Institute of South Florida operates in the Fort Lauderdale/Hollywood area but uses conventional PET/CT equipment. Grey Matters says its Davie Clinic will be the first in the U.S. to offer brain-dedicated PET scanning using the CareMiBrain system
• Academic medical centers: Massachusetts General Hospital and peers set clinical standards for amyloid PET, but their research-focused model makes them poorly positioned as accessible, patient-friendly outpatient clinics, which is the gap Grey Matters is built to fill.

Ownership and Share Structure

Management and insiders own about 11 percent of the company, and about 21 percent is owned by institutions. The rest is with retail. Top shareholders include Alpha North Asset Management with 20.52 percent, Chief Executive Officer Christopher Moreau with 5.05 percent, Chairman of the Board Harry Bloomfield with 1.97 percent, Chief Financial Officer James Kinley with 1.4 percent, and Director Rajpaul Attariwala with 1.2 percent.

Grey Matters has approximately 9.81 million shares outstanding, a market cap of CA$5.4 million, and a 52-week range of CA$0.335–CA$0.68.

Technical Analysis

Figure 2: Grey Matters Weekly Chart

Technical Analysis and Observations:

• A bull wedge with a burst of volume at the base of the wedge is in play.
• Stochastics is flashing a crossover buy signal.
• Money flow indicators MFI and OBV are surging.
• RSI is bullish.

Figure 3: Grey Matters Versus CDNX Chart

Technical Analysis and Observations:

• Grey Matters is a CDNX component stock. Money managers look for stocks that can outperform the index, and Grey seems ready to do that now.
• There's a bull wedge, and it's morphed into a rectangular base pattern.
• Stochastics is on a buy signal.

Investor Risks

• Execution & Capital: The company is pre-revenue with a ~CA$5.4 M market cap; the Davie clinic must open on schedule and generate patient volume. US$220M+ capital is needed for a 200-clinic rollout.
• Dilution: Ongoing private placements and warrant issuances could continue to dilute existing shareholders as the company funds each new clinic.
• Concentration & Competitive Entry: The imaging business is heavily dependent on a single partnership (Catalyst MedTech) and a single platform (CareMiBrain); established imaging networks could replicate the brain-specific PET model once the market validates the concept.
• Professional Advice: Before taking action with any investment, investors should consult with properly licensed, experienced, and qualified investment advisors and get numerous opinions. Failure to do so increases risk.

Investment Thesis Summary

1. First-Mover Advantage in U.S. Brain-Dedicated PET: Grey Matters is building the first network of purpose-built brain PET clinics in the U.S., with no direct competitor currently offering a seated, lower-radiation, brain-only scanning experience at scale.
2. Structural Demand Tailwind: Two FDA-approved Alzheimer's monoclonal antibody treatments require confirmation of beta-amyloid pathology by brain PET or another approved biomarker method, such as cerebrospinal fluid testing, before treatment. The growing Alzheimer's drug-development pipeline could create additional demand for PET-based patient screening and clinical-trial imaging.
3. De-Risked Near-Term Path to Revenue: The Florida Radioactive Materials License, CareMiBrain scanner delivery, ProScan reading agreement, and the separate 200-scan Catalyst MedTech LOI for the planned Tampa location collectively advance the company toward its first patient and subsequent clinic expansion.
4. Scalable Unit Economics: Each clinic is expected to generate revenue from eligible PET scans reimbursed by Medicare, Medicaid, and private insurers.
5. Additional Optionality from Legacy Pipeline: Repirinast for CKD, the DMT program for stroke/TBI, and a 20% equity stake in Seyltx (Ifenprodil for chronic cough) provide upside beyond the imaging core at no incremental cost to shareholders.
6. Bullish Charts: Charts for the global healthcare sector and Grey Matters are both bullish.

Conclusion

Grey Matters has cleared major hurdles, including licensing and clinical LOI. Potential patient revenues by September 30 are a near-term catalyst. Two FDA-approved Alzheimer's therapies require confirmation of beta-amyloid pathology by brain PET or spinal tap before treatment, and the growing Alzheimer's drug-development pipeline could create additional demand for PET-based screening and clinical-trial imaging.

Grey Matters is positioned at the intersection of that demand with a differentiated, lower-radiation, seated-patient experience that no large network currently offers. Even partial execution of the 200-clinic plan transforms this pre-revenue company into a national diagnostics platform, and the bullish stock charts imply a significant re-rating of the company could be imminent.

Stock price at time of writing (September 8, 2026): CA$0.55

Resistance Zones for Investor Profit Booking

Short-Term: CA$0.85

Medium-Term: CA$1.20

Long-Term: CA$1.65

Technical Rating: Speculative Buy

For additional disclosures, please click here.

1. Ownership and Share Structure Information

The information listed above was updated on the date this article was published and was compiled from information from the company and various other data providers.